10-Q · May 12, 2026
Rezolute, Inc. (RZLT) reported no generated revenue for Q3 2026, maintaining a net loss of $16.2 million, slightly improved from $18.9 million loss in Q3 2025. The total cash and equivalents decreased to $120.2 million…
Earnings analysis · 10-K
RZLT earnings analysis
Filed September 24, 2026 · Our reading of the company's report
The latest report
Rezolute remains a single-asset, clinical-stage biotechnology company with no revenue and a worsening annual loss trajectory, despite lower R&D spending and improved upLIFT interim response data. The failed sunRIZE…
Read full summary
Rezolute remains a single-asset, clinical-stage biotechnology company with no revenue and a worsening annual loss trajectory, despite lower R&D spending and improved upLIFT interim response data. The failed sunRIZE trial leaves the congenital HI regulatory path unresolved, while the upLIFT opportunity depends on a small, modified Phase 3 study. Near-term liquidity covers planned activities for at least 12 months, but the company expects to require additional financing for longer-term development and faces substantial contingent licensing payments.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.75
- Segment
- Single reportable clinical-stage biopharmaceutical segment; all tangible assets are located in the United States.
What stood out
-
Focused ersodetug development strategy
Rezolute remains focused on ersodetug for refractory hypoglycemia associated with congenital and tumor hyperinsulinism. The company is enrolling the Phase 3 upLIFT study in the U.S. and Europe, and the modified single-arm study may include as few as 16 participants.
-
upLIFT response signal strengthened
Interim upLIFT data improved: six of the initial eight participants met the responder criterion, and a seventh met it after the June 2026 update. Topline results are anticipated before the end of 2026.
-
Loss widened despite lower R&D
Operating expenses increased to $83.0 million from $79.9 million, while net loss widened to $77.6 million from $74.4 million. EPS improved to $(0.75) from $(0.98), largely reflecting the increase in weighted-average shares to 103.9 million from 76.0 million.
-
R&D efficiency offset by G&A growth
R&D spending declined 13% to $53.8 million from $61.5 million, including a $7.6 million reduction in ersodetug clinical and manufacturing costs. G&A increased 59% to $29.2 million from $18.4 million due partly to commercialization planning and higher compensation.
-
Liquidity supports near-term operations
The company ended fiscal 2026 with $107.8 million of capital resources, consisting of $10.6 million of cash and $97.2 million of marketable debt securities, which management believes funds planned activities for at least 12 months from the financial-statement issuance date.
-
Cash burn moderated; no dividends
Operating cash use improved to $64.6 million from $69.1 million. Capital allocation was primarily defensive and development-focused: $178.2 million of debt securities were purchased and $157.1 million matured, while financing provided only $2.2 million versus $107.3 million in the prior year; no dividends are planned.
What to watch
-
Uncertain FDA path after sunRIZE failure
The sunRIZE Phase 3 study failed its primary and key secondary endpoints. The FDA requested comprehensive datasets and summary outcomes, but as of September 2026 it was still reviewing the submission and had established no specific timeline; the FDA could require additional information or a new randomized study, changing the company’s plans, timeline and resource needs.
-
Small, modified upLIFT study may fail
The modified upLIFT design removes the double-blind randomized placebo-controlled portion and may include as few as 16 participants. The company explicitly cautions that the modifications may not demonstrate efficacy and that the study may fail its primary or secondary endpoints, putting the principal near-term development catalyst at risk.
-
Additional financing and milestone burden
Rezolute has no meaningful revenue, incurred a $77.6 million net loss and used $64.6 million in operating cash during fiscal 2026. Management states that additional equity or debt financing will be needed for long-term liquidity, while a $25.0 million milestone is due upon regulatory approval and additional license milestones could total up to $202.5 million for ersodetug and the PKI portfolio.
-
Potential securities litigation
Following the sunRIZE result, several law firms announced investigations seeking shareholders to pursue potential securities-law claims. No lawsuit was pending or threatened as of June 30, 2026, but the filing notes that litigation could require significant financial and management resources.
Management's outlook
No numeric revenue or EPS guidance was provided. Management expects upLIFT topline results before the end of calendar 2026 and, assuming supportive data, plans to submit an FDA Biologics License Application for ersodetug in mid-2027. The FDA has not established a specific timeline for reviewing the congenital HI sunRIZE data.
Earlier filings 4
10-Q · February 12, 2026
Rezolute reported no revenue and a wider quarterly net loss of $22.774 million (three months ended December 31, 2025) versus $15.730 million in the prior-year quarter, with GAAP loss per share of $(0.22). Cash and cash…
10-Q · May 13, 2025
Rezolute reported a net loss of $18.9M (three months ended March 31, 2025) and GAAP diluted loss per share of $(0.27). Operating expenses rose as R&D increased to $15.283M (Q3) and total operating loss widened to…
10-K · September 19, 2024
Rezolute advanced its lead program ersodetug into pivotal Phase 3 programs (sunRIZE for congenital HI and a Phase 3 registrational study for tumor HI) with topline readouts expected in calendar 2025, and reported…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.